for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SINOPHARM HOLDING CO LTD

1099.HK

Latest Trade

27.40HKD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

25.70

 - 

41.00

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
27.40
Open
--
Volume
--
3M AVG Volume
122.44
Today's High
--
Today's Low
--
52 Week High
41.00
52 Week Low
25.70
Shares Out (MIL)
2,971.66
Market Cap (MIL)
81,423.38
Forward P/E
11.54
Dividend (Yield %)
2.45

Next Event

Q3 2019 SINOPHARM GROUP CO LTD Earnings Release

Latest Developments

More

Sinopharm Group Posts HY Profit Attributable Of RMB2.98 Bln

Sinopharm Group Co Says Qtrly Net Profit Attributable RMB 1.14 Billion Versus RMB 891.6 Million

Sinopharm Group Posts FY Net Profit Of RMB9,404.48 MLN, UP 8.53 PCT

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SINOPHARM HOLDING CO LTD

Sinopharm Group Company Limited is principally engaged in the distribution of pharmaceutical products and medical equipment. The Company operates through three business segments. The Pharmaceutical Distribution segment is engaged in the distribution of medicines, medicine devices and pharmaceutical products to hospitals, other distributors, retail drug stores and clinics. The Retail Pharmacy segment is engaged in the operation of medicine chain stores. The Other Business segment is engaged in the distribution of laboratory supplies, the manufacture and distribution of chemical reagents, as well as the production and sales of pharmaceutical products. The Company is also engaged in the provision of pharmaceutical logistics services and property rental business in China through its subsidiaries.

Industry

Biotechnology & Drugs

Contact Info

No. 1001 Zhongshan West Road

+86.21.23052666

http://www.sinopharmgroup.com.cn/

Executive Leadership

Zhiming Li

Executive Chairman of the Board and Deputy Secretary of Party Committee

Yong Liu

President, Executive Director

Qiyu Chen

Non-Executive Vice Chairman of the Board

Xiuchang Jiang

Chief Financial Officer, Vice President

Maisong Cai

Vice President

Key Stats

2.00 mean rating - 20 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

258.4K

2017

277.7K

2018

344.5K

2019(E)

400.8K
EPS (CNY)

2016

1.680

2017

1.910

2018

1.960

2019(E)

2.135
Price To Earnings (TTM)
12.45
Price To Sales (TTM)
0.19
Price To Book (MRQ)
1.67
Price To Cash Flow (TTM)
5.93
Total Debt To Equity (MRQ)
166.96
LT Debt To Equity (MRQ)
18.84
Return on Investment (TTM)
21.78
Return on Equity (TTM)
4.44

Latest News

Sinopharm buys 60 pct device distributor for $765 mln

Pharmaceutical products distributor Sinopharm Group Co Ltd said late on Wednesday it would buy 60 percent of a medical devices distributor from the controlling parent company for 5.11 billion yuan ($765.4 million), as it aims to expand market share in its medical device...

BRIEF-Sinopharm Group Posts Qtrly Net Profit Attributable RMB842.7 Million

* QTRLY TOTAL OPERATING REVENUE RMB72.69 BILLION VERSUS RMB68.42 BILLION

BRIEF-Sinopharm Group Co Expects Q1 Net Profit Attributable Down About 30%

* EXPECTS Q1 NET PROFIT ATTRIBUTABLE TO RECORD DECLINE OF ABOUT 30%

BRIEF-Sinopharm Group Co Posts ‍FY Profit Of RMB5.28 Bln

* FY PROFIT ATTRIBUTABLE RMB 5.28 BILLION VERSUS RMB 4.65 BILLION Source text for Eikon: Further company coverage:

BRIEF-Sinopharm Group Co's Board Resolves To Propose Issue Of Corporate Bonds In China

* BOARD RESOLVED TO PROPOSE ISSUE OF CORPORATE BONDS IN PRC; ISSUE SIZE OF NO MORE THAN RMB10 BILLION Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

BRIEF-Sinopharm Group posts ‍9-mnth profit attributable of RMB ‍3.66​ billion​

* 9-month net profit attributable to equity holders of co RMB 3.66 billion versus RMB3.60 billion

BRIEF-Sinopharm Group clarifies on research report published by a financial research company

* Aware of research report published by a financial research company questioning co's accounting recognition of operating cash flow

BRIEF-Sinopharm Group Co appoints Li Zhiming as chairman

* Resolved to elect Li Zhiming as chairman of board and Chen Qiyu as vice chairman Source text for Eikon: Further company coverage:

BRIEF-China Ludao Technology Co announces formation of JV

* Ludao PRC, Sinopharm TCM and Lu Xian Cao Tang entered into capital contribution agreement

BRIEF-Sinopharm Group Co Ltd posts HY profit attributable rmb2.76 billion

* HY profit attributable to owners of parent RMB2.76 billion versus RMB2.53 billion

BRIEF-Sinopharm Group Co records FY net profit of RMB6.89 billion, an increase of 20.04 pct

* Recorded a fy net profit of rmb6,891.60 million, representing an increase of rmb1,150.69 million or 20.04%

BRIEF-Fujian Cosunter Pharmaceutical in strategic agreement with Sinopharm Group

* Says it signs strategic cooperation agreement with Sinopharm Group Co Ltd

BRIEF-Sinopharm resolves to propose issue of asset-backed securities in China

* it resolved on 9 november 2016 to propose issue of asset-backed securities in PRC.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up